Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wellbeingtox is a botulinum toxin type A injectable product marketed by Wells PharmTech for aesthetic and cosmetic applications. It is primarily indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity. The product functions by blocking the release of acetylcholine at the neuromuscular junction, resulting in temporary muscle paralysis and a reduction in the appearance of dynamic wrinkles. It is typically provided as a lyophilized powder in 100-unit vials for reconstitution and intramuscular injection. Wells PharmTech operates as a B2B supplier of aesthetic products, and Wellbeingtox is part of their portfolio of cosmetic injectables.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wellbeingtox.